


GSK-LSD1

Cat. No.:	HY-100546
CAS No.:	1431368-48-7
Molecular Formula:	C ₁₄ H ₂₀ N ₂
Molecular Weight:	216.32
Target:	Histone Demethylase
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

GSK-LSD1 is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis^{[1][2][3]}.

CUSTOMER VALIDATION

- Signal Transduct Target Ther. 2022 Apr 13;7(1):102.
- Adv Mater. 2021 May;33(18):e2100949.
- Nat Commun. 2021 Dec 8;12(1):7142.
- Cytokine. 2022 Jan 5;151:155789.
- Patent. US20180263995A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Ramms B, et al. Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity. *Diabetes*. 2022 Dec 1;71(12):2513-2529.
- [2]. Alsaqer SF, et al. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. *Oncotarget*. 2017 Jul 27;8(43):73372-73386.
- [3]. Hong KS, et al. GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro. *Signal Transduct Target Ther*. 2020 Nov 17;5(1):267.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA